Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): a report from the Pediatric Preclinical Testing Program

BACKGROUND: Selinexor (KPT-330) is an inhibitor of the major nuclear export receptor, exportin 1 (XPO1, also termed chromosome region maintenance 1, CRM1) that has demonstrated activity in preclinical models and clinical activity against several solid and hematological cancers. PROCEDURES: Selinexor...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Pediatr Blood Cancer
Egile Nagusiak: Attiyeh, Edward F., Maris, John M., Lock, Richard, Reynolds, C. Patrick, Kang, Min H., Carol, Hernan, Gorlick, Richard, Kolb, E. Anders, Keir, Stephen T., Wu, Jianrong, Landesman, Yosef, Shacham, Sharon, Lyalin, Dmitry, Kurmasheva, Raushan T., Houghton, Peter J., Smith, Malcolm A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2015
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4722540/
https://ncbi.nlm.nih.gov/pubmed/26398108
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.25727
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak